2019 ERC Proof of Concept grant for Prof. Esther Lutgens

Under the European Research Council Proof of Concept grant initiative, ERC grantees may now also apply for additional funding to set up, namely, an Intellectual Property Rights (IPR) strategy for the results of their prior ERC project. The funds are granted at the earliest stage of innovation and therefore researchers now have the necessary support to bring their research to the market.

Prof. Esther Lutgens (Ludwig Maximilians-University, Munich, Germany) successfully applied for such a grant on her work in the field of atherosclerosis-specific immunity modulators. In specific, this project will study inhibition of CD40-TRAF6 interactions as a highly potent and selective therapeutic strategy for cardiovascular disease. This work builds on recent findings published in the following paper: “Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis.” in the Journal of the American College of Cardiology in 2018: https://www.ncbi.nlm.nih.gov/pubmed/29406859

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.